title: [The effect of a simvastatin and ezetimib combination on blood lipids and cardiovascular events in diabetic patients (comments on the subanalysis results within the IMPROVE-IT study)].
abstract: IMPROVE-IT study demonstrated that the addition 10 mg of ezetimibe to 40 mg of simvastatin in patients after acute coronary syndrome reduces significantly not only their LDL-cholesterol, but also the number of cardiovascular events. Recently published subanalysis of this study was focused on whether these combinations of drugs is more preferable for patients with diabetes mellitus or for patients without diabetes. The addition of ezetimibe to a simvastatin resulted in a greater decline of LDL-cholesterol level in diabetic group than in patients without diabetes. In patients with diabetes mellitus their cardiovascular morbidity and mortality were decreased significantly; reduction of these clinical end-points in the group of patients without diabetes were not statistically significant.
authors.forename: Vladimír
authors.initials: V
authors.lastname: Soška
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003920:Diabetes Mellitus / Q000097:blood*; D005060:Europe / Q000453:epidemiology; D000069499:Ezetimibe, Simvastatin Drug Combination / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000069499:Ezetimibe, Simvastatin Drug Combination